Marginum

Marginum is medical technology startup developing fluorescence-based tissue detection systems. We improve surgical tissue monitoring with data-driven solutions.

[Samu Lehtonen M.D. @SamuJRLehtonen]

Happy to be featured in @NuoriLaakari, the magazine of the Finnish Junior Doctors’ Association, reflecting on building medtech companies in Finland.

A look back at @Marginum’s journey from early research to CE-marked device, HIVEN®, used in 100+ operations across 15 countries.🎯

[Samu Lehtonen M.D. @SamuJRLehtonen]

I’m truly honoured to have been selected as Young Entrepreneur of the Year 2026.

A heartfelt thank you to Kuopio Entrepreneurs for this recognition and to the entire @MarginumLtd team, as well as our customers and partners. 🙌

https://t.co/w9xQrjrsIv

[Marginum @MarginumLtd]

Marginum HIVEN® wins Red Dot Design Award 2026.

#HIVEN was recognised by the @reddot jury for its outstanding design and quality, user-centred design, intuitive interaction, and seamless integration into surgical workflow.
https://t.co/c6cL85wubi

[Marginum @MarginumLtd]

Major milestone for Marginum 🇺🇸✨

U.S. clinical trial launched at @UIHealth in Chicago. The first-in-human surgical treatment in the United States has been successfully completed. An important step toward making HIVEN® available to U.S. surgeons. 👏

https://t.co/HPPOcCOVxk

[Marginum @MarginumLtd]

Marginum is proud to announce a new collaboration with ALMEDA, a Prague-based medical equipment distributor, to bring the CE-marked HIVEN® device to the Czech Republic & Slovakia, expanding access to our advanced aspirate tissue monitoring technology. 🇨🇿🇸🇰
https://t.co/4iesJ0MUYm

[Marginum @MarginumLtd]

Landmark HIVEN® first-in-human study published in Neuro-Oncology Advances.

Key findings:
📊 5-ALA fluorescence detected +483% more often and +613% longer vs visual
💡ATM appeared safe and value-adding
🛡️No device-related AEs; expert agreement 96.7%

https://t.co/UM038hk4ZW

[Marginum @MarginumLtd]

Season’s Greetings from Marginum!✨

2025 highlights:
⚖️ HIVEN® achieved EU MDR certification
🔬 Multinational clinical trials launched
🤝 Distribution partnerships expanded across Europe
🚀 €2.5M raised to secure U.S. FDA clearance

Thank you, team & partners. Onward to 2026!❤️

[Marginum @MarginumLtd]

🚀 The Finnish Medical Foundation @LaaketieteenS has announced the nominees for the Pohjola Medical Innovation Award, with @MarginumLtd and CEO @SamuJRLehtonen among the top three. 🏆 Winner announced at the Finnish Medical Convention in January 2026.

https://t.co/2dA9XWUsMh

[Marginum @MarginumLtd]

@SamuJRLehtonen and Antti-Pekka Elomaa of @MarginumLtd were named top Finnish healthcare influencers for 2025 by @DuodecimFi for their work with the HIVEN® device and the aspirate tissue monitoring method for cancer surgery. Congrats! 🎉

https://t.co/zyCQz5Rikx

[Marginum @MarginumLtd]

Next stop: #BeahrsSummit2025! ✨ Excited to join surgical innovators on Nov 18 and showcase our CE-marked aspirate tissue monitoring technology.

📌 Visit Marginum at the Mayo Civic Center, 2nd floor, table 30, and learn more about the #HIVEN® solution: https://t.co/uIGrw0xCw8

[Marginum @MarginumLtd]

🎉Marginum has been selected for @BusinessFinland's prestigious Young Innovative Companies (YIC) program 🇫🇮✨

Through YIC, we’ll receive up to 1 M€ to accelerate HIVEN® technology’s global market expansion🌍 https://t.co/q3FvFIeD53

[Marginum @MarginumLtd]

HIVEN® Usability Assessment completed at the @uiccom Surgical Innovation and Training Laboratory in the U.S. In collaboration with @thisisUIC, IRB approval was obtained for an interventional study starting this autumn. 🎉
https://t.co/NUqlbabrET

[Marginum @MarginumLtd]

Marginum is proud to announce a new collaboration with Thomy F.E., d.o.o. to distribute the EU MDR-certified HIVEN® device in Slovenia, Croatia & Bosnia and Herzegovina, expanding access to advanced aspirate tissue monitoring technology. 🌍
https://t.co/YeSAdCZgsX

[MBA SURGICAL EMPOWERMENT @MBA_eu]

Es un placer anunciar que hemos firmado un acuerdo con @MarginumLtd , empresa finlandesa de tecnología médica pionera en sistemas de detección de tejidos basados en fluorescencia, que nos permitirá distribuir en España y Portugal, HIVEN®, una tecnología única para la cirugía oncológica cerebral que facilita una resección más segura y precisa.

#neurocirugía

[Marginum @MarginumLtd]

Next stop: #EANO2025 in Prague, 16-19 October. Please stop by to see our CE-marked HIVEN® Aspirate Tissue Monitoring solution!

📌 Visit Marginum’s booth in the forum hall foyer, 2nd floor, near the video wall G

[Marginum @MarginumLtd]

Marginum teams up with @MBA_eu to bring the CE-marked HIVEN® device to Spain & Portugal. 🌍 Designed for the treatment of high-grade gliomas like glioblastoma, HIVEN® could benefit 2,000+ patients annually on the Iberian Peninsula. 🧠

https://t.co/l2fakfY84r

[Marginum @MarginumLtd]

Join us at #EANS2025 in Vienna for the launch of our CE-marked HIVEN® device, designed for fluorescence-guided surgery of high-grade gliomas in which 5-ALA is used.🧠Thank you, @EANSonline50, for having us!

📌 Visit Marginum at booth #48 to learn more.

[Marginum @MarginumLtd]

🔔 Big news: HIVEN® by Marginum has received CE Mark approval! 🔔

HIVEN® provides real-time margin assessment during surgery and is now cleared for clinical use across the EU and other CE-recognising regions – supporting safer surgical decision-making.

https://t.co/rXBvJcWb0l

[Marginum @MarginumLtd]

🎉 Marginum raises €2.5M in Pre-Series A funding to launch U.S. clinical trials and for HIVEN® market expansion. Thank you to our investors for their continued trust and to our new partners for joining us in shaping the future of surgery. 💡

https://t.co/tfVqjK7SOH

[Marginum @MarginumLtd]

Marginum is proud to announce a collaboration with Mediplast AB to distribute Marginum’s innovative HIVEN® aspirate tissue monitoring technology in Sweden, Norway, Denmark and Finland – facilitating access to cutting-edge surgical solutions. 🚀📌

https://t.co/UYS17uIjgz